EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 375 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Today is Random Acts of Kindness Day February 17, 2021 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... November 3, 2020 Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients... March 18, 2026 Load more HOT NEWS Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy... Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life The Future Front Line: Pre-Med During COVID-19 Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did...
